This page contains a Flash digital edition of a book.
Triamcinolone Acetonide for the Treatment of Diabetic Macular Oedema


triamcinolone acetonide for diffuse diabetic macular edema, Ophthalmology, 2005;112:1557–63.


47. Ozdek S, Bahceci UA, Gurelik G, et al., Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema, J Diabetes Complications, 2006;20:246–51.


48. Choi YJ, Oh IK, Oh JR, et al., Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema, Korean J Ophthalmol, 2006;20:205–9.


49. Bakri SJ, Kaiser PK, Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema, Am J Ophthalmol, 2005;139:290–4.


50. Cellini M, Pazzaglia A, Zamparini E, et al., Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema, BMC Ophthalmol, 2008;8:5.


51. Veritti D, Lanzetta P, Perissin L, et al., Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up, Invest Ophthalmol Vis Sci, 2009;50:2391–7.


52. Cardillo JA, Souza-Filho AA, Oliveira AG, Intravitreal bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulness for the treatment of diabetic macular edema, Arch Soc Esp Oftalmol, 2006;81:675–82.


53. Lim JI, Hung D, Fung AE, et al., One-year results of a phase 1 study evaluating the safety and evidence of efficacy of a single intravitreal injection of the Verisome™ liquid drug delivery system for sustained release of low-dose triamcinolone (IBI-20089) in eyes with cystoid macular edema, Presented at: 82nd Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, US, 2–6 May 2010.


54. Fung AE, One-year safety and efficacy of an injectable, sustained-delivery, liquid steroid for treatment of macular edema due to retinal vein occlusion, Presented at: Angiogenesis 2010, Miami, Florida, US, 20 February 2010.


55. Kuppermann BD, Blumenkranz MS, Haller JS, et al., Randomized, controlled study of a novel intravitreous dexamethasone drug delivery system in patients with persistent macular edema, Arch Ophthalmol, 2007;125:309–17.


56. Pearson P, Comstock T, Ip M, et al., Fluocinolone acetonide intravitreal implant for diabetic macular edema: 3-year multicenter, randomized, controlled, clinical trial, Ophthalmology, 2011;118:1580–7.


57. Scott IU, Flynn HW, Reducing the risk of endophthalmitis following intravitreal injections, Retina, 2007;27:10–2.


58. Benz MS, Murray TG, Dubovy SR, et al., Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone, Arch Ophthalmol, 2003;121:271–3.


59. Jonas JB, Bleyl U, Morphallaxia-like ocular histology after intravitreal triamcinolone acetonide, Br J Ophthalmol, 2004;88:839–40.


60. Jonas JB, Kreissig I, Degenring RF, Endophthalmitis after intravitreal injection of triamcinolone acetonide, Arch Ophthalmol, 2003;121:1663–4.


61. Jonas JB, Kreissig I, Spandau UH, et al., Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide, Am J Ophthalmol, 2006;141:579–80.


62. Kreissig I, Degenring RF, Jonas JB, Intravitreal triamcinolone acetonide. Complication of infectious and sterile endophthalmitis, Ophthalmologe, 2006;103:30–4.


63. Moshfeghi DM, Kaiser PK, Scott IU, et al., Acute endophthalmitis following intravitreal triamcinolone acetonide injection, Am J Ophthalmol, 2003;136:791–6.


64. Parke DW, Intravitreal triamcinolone and endophthalmitis, Am J Ophthalmol, 2003;136:918–9.


65. Westfall AC, Osborn A, Kuhl D, et al., Acute endophthalmitis incidence: intravitreal triamcinolone, Arch Ophthalmol, 2005;123:1075–7.


66. Nelson ML, Tennant MT, Sivalingam A, et al., Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection, Retina, 2003;23:686–91.


67. Sutter FK, Gillies MC, Pseudo-endophthalmitis after intravitreal injection of triamcinolone, Br J Ophthalmol, 2003;87:972–4.


68. Moshfeghi AA, Scott IU, Flynn HW, et al., Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema, Am J Ophthalmol, 2004;138:489–92.


69. Roth DB, Chieh J, Spirn MJ, et al., Noninfectious endophthalmitis associated with intravitreal triamcinolone injection, Arch Ophthalmol, 2003;121:1279–82.


70. Agrawal S, Agrawal J, Agrawal TP, Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide, Am J Ophthalmol, 2004;138:679–80.


71. Viola F, Morescalchi F, Staurenghi G, Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone, Arch Ophthalmol, 2006;124:133–4.


72. Park HY, Yi K, Kim HK, Intraocular pressure elevation after intravitreal triamcinolone acetonide injection, Korean J Ophthalmol, 2005;19:122–7.


73. Bakri SJ, Beer PM, The effect of intravitreal triamcinolone acetonide on intraocular pressure, Ophthalmic Surg Lasers Imaging, 2003;34:386–90.


74. Bui Quoc E, Bodaghi B, Adam R, et al., Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis, J Fr Ophtalmol, 2002;25:1048–56.


75. Chan CK, Fan DS, Chan WM, et al., Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study, Eye, 2005;19:625–30.


76. Detry-Morel M, Escarmelle A, Hermans I, Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide, Bull Soc Belge Ophtalmol, 2004;292:45–51.


77. Gillies MC, Kuzniarz M, Craig J, et al., Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract, Ophthalmology, 2005;112:139–43.


78. Gillies MC, Simpson JM, Billson FA, et al., Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial, Arch Ophthalmol, 2004;122:336–40.


79. Jonas JB, Degenring RF, Kreissig I, et al., Intraocular pressure elevation after intravitreal triamcinolone acetonide injection, Ophthalmology, 2005;112:593–8.


80. Jonas JB, Kreissig I, Degenring R, Intraocular pressure after intravitreal injection of triamcinolone acetonide, Br J Ophthalmol, 2003;87:24–7.


81. Jonas JB, Degenring R, Kreissig I, et al., Safety of intravitreal high-dose reinjections of triamcinolone acetonide, Am J Ophthalmol, 2004;138:1054–5.


82. Jonas JB, Kreissig I, Degenring R, Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide, Arch Ophthalmol, 2003;121:729–30.


83. Ozkiris A, Erkilic K, Complications of intravitreal injection of triamcinolone acetonide, Can J Ophthalmol, 2005;40:63–8.


84. Singh IP, Ahmad SI, Yeh D, et al., Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection, Am J Ophthalmol, 2004;138:286–7.


85. Smithen LM, Ober MD, Maranan L, et al., Intravitreal triamcinolone acetonide and intraocular pressure, Am J Ophthalmol, 2004;138:740–3.


86. Jonas JB, Degenring R, Vossmerbauemer U, et al.,


Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide, Eur J Ophthalmol, 2005;15:462–4.


87. Gillies MC, Islam FM, Zhu M, et al., Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema, Br J Ophthalmol, 2007;91:1323–6.


88. Cekic O, Chang S, Tseng JJ, et al., Cataract progression after intravitreal triamcinolone injection, Am J Ophthalmol, 2005;139:993–8.


89. Jaissle GB, Szurman P, Bartz-Schmidt KU, Ocular side effects and complications of intravitreal triamcinolone acetonide injection, Ophthalmologe, 2004;101:121–8.


90. Kai W, Yanrong J, Xiaoxin L, Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density, Graefes Arch Clin Exp Ophthalmol, 2006;244:1152–9.


91. Macky TA, Helmy D, El Shazly N, Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study, Graefes Arch Clin Exp Ophthalmol, 2007;245:817–24.


92. Lang Y, Zemel E, Miller B, et al., Retinal toxicity of intravitreal kenalog in albino rabbits, Retina, 2007;27:778–88.


93. Yeung CK, Chan KP, Chan CK, et al., Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone, Jpn J Ophthalmol, 2004;48:236–42.


94. Tokuda K, Tsukamoto T, Fujisawa S, et al., Evaluation of toxicity due to vital stains in isolated rat retinas, Acta Ophthalmol Scand, 2004;82:189–94.


95. Kivilcim M, Peyman GA, El-Dessouky ES, et al., Retinal toxicity of triamcinolone acetonide in silicone-filled eyes, Ophthalmic Surg Lasers, 2000;31:474–8.


96. Narayanan R, Mungcal JK, Kenney MC, et al., Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells, Invest Ophthalmol Vis Sci, 2006;47:722–8.


97. Yeung CK, Chan KP, Chiang SW, et al., The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone, Invest Ophthalmol Vis Sci, 2003;44:5293–300.


98. Schatz H, Madeira D, McDonald HR, et al., Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema, Arch Ophthalmol, 1991;109:1549–51.


99. Guyer DR, D’Amico DJ, Smith CW, Subretinal fibrosis after laser photocoagulation for diabetic macular edema, Am J Ophthalmol, 1992;113:652–6.


100. Prskavec FH, Fulmek R, Klemen C, et al., Changes in the visual field and dark adaptation following panretinal photocoagulation in diabetic retinopathy, Klin Monatsbl Augenheilkd, 1986;189:385–7.


101. Stanga PE, Reck AC, Hamilton AM, Micropulse laser in the treatment of diabetic macular edema, Semin Ophthalmol, 1999;14:210–3.


102. Laursen ML, Moeller F, Sander B, et al., Subthreshold micropulse diode laser treatment in diabetic macular oedema, Br J Ophthalmol, 2004;88:1173–9.


103. Luttrull JK, Musch DC, Mainster MA, Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema, Br J Ophthalmol, 2005;89:74–80.


104. Sivaprasad S, Sandhu R, Tandon A, et al., Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up, Clin Experiment Ophthalmol, 2007;35:640–4.


105. Lanzetta P, Polito A, Veritti D, Subthreshold laser, Ophthalmology, 2008;115:216.


EUROPEAN ENDOCRINOLOGY


47


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68